0001415889-24-015151.txt : 20240603
0001415889-24-015151.hdr.sgml : 20240603
20240603161510
ACCESSION NUMBER: 0001415889-24-015151
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240530
FILED AS OF DATE: 20240603
DATE AS OF CHANGE: 20240603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GORDON CARL L
CENTRAL INDEX KEY: 0001282930
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39264
FILM NUMBER: 241013770
MAIL ADDRESS:
STREET 1: 601 LEXINGTON AVENUE
STREET 2: 54TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Keros Therapeutics, Inc.
CENTRAL INDEX KEY: 0001664710
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 811173868
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 617-314-6297
MAIL ADDRESS:
STREET 1: 1050 WALTHAM STREET, SUITE 302
CITY: LEXINGTON
STATE: MA
ZIP: 02421
4
1
form4-06032024_040605.xml
X0508
4
2024-05-30
0001664710
Keros Therapeutics, Inc.
KROS
0001282930
GORDON CARL L
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
LEXINGTON
MA
02421
true
false
false
false
0
Stock Option (right to buy)
46.31
2024-05-30
4
A
0
10000
0
A
2034-05-29
Common Stock
10000
10000
D
The option shall vest in equal quarterly installments over the 12 months following the date of grant, provided that the grant will in any case be fully vested on the date of Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.
/s/ Keith Regnante, Attorney-in-Fact
2024-06-03